Does testosterone therapy increase hematocrit and risk erythrocytosis?

Testosterone replacement therapy (TRT) is well-established as a potent stimulant of red blood cell production, making erythrocytosis (an abnormally high volume of red blood cells) the most common adverse effect associated with its use.

Clinical evidence

The impact of testosterone on hematocrit is both dose-dependent and highly sensitive to the method of administration.

• Effect Size: Meta-analyses of randomized controlled trials (RCTs) involving 51 studies show that TRT is associated with a significant mean increase in hematocrit of 3.19% (95% CI, 2.19 to 4.19).
• Incidence: In a study of 423 men, 12.8% developed erythrocytosis (hematocrit > 52%). This risk escalates with injectable formulations; research suggests up to 20% to 40% of men using injectable testosterone develop erythrocytosis, compared to much lower rates with transdermal gels.
• Cardiovascular Correlation: Large cohort studies have identified that men reaching a hematocrit threshold of ≥52% within the first year of TRT have an increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE).

Mechanistic explanations

Testosterone increases red blood cell mass through a complex, multi-pathway process known as secondary erythrocytosis:

• Hepcidin Suppression: Testosterone suppresses hepcidin, the master regulator of iron homeostasis. Lower hepcidin levels increase iron absorption and mobilization, providing more raw material for hemoglobin synthesis.
• EPO Stimulation: It directly stimulates the release of erythropoietin (EPO) from the kidneys and may recalibrate the EPO-hemoglobin set point, maintaining higher red cell levels over time.
• Bone Marrow Activity: Testosterone acts directly on erythroid progenitor cells in the bone marrow and reduces the clearance of older (senescent) red blood cells, further inflating the hematocrit count.

Clinical implications

Guidelines from the American Urological Association (AUA) and the Endocrine Society recommend regular monitoring of hematocrit during TRT. A threshold of 54% is generally considered the "red line" requiring clinical intervention, such as dose adjustment, switching to topical formulations, or therapeutic phlebotomy.

Bottom line

Testosterone therapy significantly increases hematocrit by suppressing hepcidin and boosting erythropoietin. This leads to a high risk of erythrocytosis, particularly with injectable formulations, requiring consistent clinical monitoring to mitigate potential cardiovascular risks.